×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| Concord Biotech Limited | 2176.65 | 425.65 | 2039.88 | 4.07 | 16,852 | 47.3 |
| CAPLIN POINT LABORATORIES LTD. | 2146.0 | 858.9 | 1825.7 | 11.26 | 16647 | 29.4 |
| NATCO PHARMA LTD. | 12523.0 | 4641.0 | 11927.0 | 25.91 | 15186 | 8.9 |
Concord Biotech Limited, with Security Code 543960, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 194.8 | 262.3 | 240.8 | 319.0 | 215.8 | 310.2 | 244.2 | 429.9 | 204.0 |
| Expenses | 122.7 | 143.2 | 134.9 | 184.7 | 134.5 | 173.5 | 146.3 | 239.4 | 142.6 |
| Operating Profit | 72.2 | 119.2 | 105.9 | 134.3 | 81.3 | 136.7 | 98.0 | 190.5 | 61.4 |
| OPM % | 37.03% | 45.43% | 43.99% | 42.1% | 37.66% | 44.06% | 40.11% | 44.31% | 30.1% |
| Other Income | 6.7 | 8.1 | 8.2 | 10.8 | 10.3 | 10.0 | 14.7 | 9.4 | 13.7 |
| Interest | 0.8 | 0.8 | 0.5 | 0.5 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 |
| Depreciation | 13.0 | 13.3 | 13.5 | 13.7 | 13.2 | 13.3 | 13.3 | 14.6 | 17.8 |
| Profit before tax | 65.0 | 113.2 | 100.1 | 130.9 | 78.2 | 133.3 | 99.3 | 185.2 | 57.2 |
| Tax % | -25.4% | -25.3% | -25.5% | -25.7% | -25.5% | -26% | -25.4% | -23.3% | 25.6% |
| Net Profit | 48.5 | 84.5 | 74.6 | 97.2 | 58.2 | 98.7 | 74.1 | 141.9 | 42.6 |
| EPS in Rs | 4.63 | 8.08 | 7.13 | 9.29 | 5.57 | 9.43 | 7.08 | 0 | 4.07 |
| Metrics | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 194.8 | 262.3 | 240.8 | 319.0 | 215.8 | 310.2 | 244.2 | 429.9 |
| Expenses | 122.7 | 146.6 | 134.9 | 186.9 | 134.5 | 176.5 | 146.3 | 240.9 |
| Operating Profit | 72.2 | 115.7 | 105.9 | 132.1 | 81.3 | 133.7 | 98.0 | 188.9 |
| OPM % | 37.03% | 44.11% | 43.99% | 41.41% | 37.66% | 43.11% | 40.11% | 43.95% |
| Other Income | 6.7 | 8.1 | 8.2 | 10.8 | 10.3 | 10.0 | 14.7 | 9.4 |
| Interest | 0.8 | 0.8 | 0.5 | 0.5 | 0.2 | 0.1 | 0.1 | 0.1 |
| Depreciation | 13.0 | 13.3 | 13.5 | 13.7 | 13.2 | 13.3 | 13.3 | 14.6 |
| Profit before tax | 65.0 | 109.7 | 100.1 | 128.7 | 78.2 | 130.3 | 99.3 | 183.6 |
| Tax % | -25.4% | -25.3% | -25.5% | -25.7% | 25.5% | 26% | 25.4% | -23.3% |
| Net Profit | 54.5 | 81.0 | 77.6 | 95.0 | 59.6 | 95.7 | 75.9 | 140.4 |
| EPS in Rs | 5.21 | 7.74 | 7.41 | 9.08 | 5.7 | 9.15 | 7.26 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 18% |
| 3 Years: | 18% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 20% |
| 3 Years: | 9% |
| TTM: | 9% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| 1 Year: | 5% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 18% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 9% |
| TTM: | 7% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| 1 Year: | 5% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|